New treatments for Hodgkin’s disease

Current Treatment Options in Oncology

Volumn 3, Issue 4, 2002, Pages 283-290

  Glossmann, Jan Peter ^a   Josting, Andreas ^a   Diehl, Volker ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Autologous Stem Cell Transplantation; Extend Field Irradiation; Freedom From Treatment Failure; Involve Field; Stanford Versus

Indexed keywords

ANTINEOPLASTIC AGENT; BEACOPP PROTOCOL; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; PREDNISONE; PROCARBAZINE; RADIOTHERAPY; VINCRISTINE;

EID: 0036676374     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-002-0028-x     Document Type: Article

References (38)

1. Carde P, Burger JM, Henry-Amar M: Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988, 6:239–248.
2. Loeffler M, Pfreundschuh M, Rühl U: Risk factor adapted treatment of Hodgkin’s lymphoma: strategies and perspectives. Recent Results Cancer Res 1989, 117:142–162.
3. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998, 339:1506–1514. DOI: 10.1056/NEJM199811193392104
4. Sarris A, Kliche K, Pethambaram P, et al.: Interleukin-10 levels are often elevated in serum of adults with Hodgkin’s disease and are associated with inferior failure-free survival. Ann Oncol 1999, 10:433–439. DOI: 10.1023/A:1008301602785
5. von Wasielewski R, Seth S, Franklin J, et al.: Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin’s disease allowing for known prognostic factors. Blood 2000, 95: 1207–1213.
6. Duhmke E, Franklin J, Pfreundschuh M, et al.: Low-dose radiation is sufficient for the noninvolved extendedfield treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001 19:2905–2914.
7. Carde P, Noordijk E, Hagenbeek A: Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 1997, 16:13.
8. Diehl V, Sieber M, Rüffer U: Treatment of early-stage Hodgkin’s disease: considerations in the use of chemotherapy. Annual Meeting of American Society of Clinical Oncology, Los Angeles, CA, 1998.
9. Engert A, Schiller P, Pfistner B, et al.: Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients (pts) with intermediate-stage Hodgkin’s disease (HD): randomized multicenter study. Blood 2001, 98:3199a.
10. De Vita VT Jr, Simon RM, Hubbard G, et al.: Curability of advanced Hodgkin’s disease with chemotherapy: longterm follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587–595.
11. Bonadonna G, Zucali R, Monfardini S, et al.: Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252–260. DOI: 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7
12. Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478–1485. DOI: 10.1056/NEJM199211193272102
13. Connors JM, Klimo P, Adams G, et al.: Treatment of advanced Hodgkin’s disease with chemotherapy— comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997, 15:1638–1645.
14. Sieber M, Rueffer U, Tesch H: Rapidly alternating COPP+ABV+IMEP CAI is equally effective as alternating COPP+ABVD CA for Hodgkin’s disease: final results of two randomised trials for intermediate HD5 protocol) and advanced HD6 protocol stages.tLeuk Lymphoma 1998, 29:93.
15. Carde P, MacKintosh F, Rosenberg S, et al.: A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol 1983, 1:146–153.
16. Bartlett N, Rosenberg S, Hoppe R, et al.: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 1995, 13:1080–1088.
17. Diehl V, Franklin J, Hasenclever D, et al.: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1998, 16:3810–3819.
18. Diehl V, Franklin J, Paulus U, et al.: BEACOPP chemotherapy with dose escalation in advanced Hodgkin’s disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 2001, 98:3202a.
19. Loeffler M, Brosteanu O, Hasenclever D, et al.: Metaanalysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 1998, 16:818–829.
20. Cannellos G, Young RC, De Vita VD: Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharmacol Ther 1972, 13:750–758.
21. Santoro A, Viviani S, Villarreal C, et al.: Salvage chemotherapy in Hodgkin’s disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986, 70:343–351.
22. Longo D, Duffey P, Young R, et al.: Conventionaldose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992, 10:210–219.
23. Santoro A, Viviani S, Valagussa P, et al.: CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin’s disease. Semin Oncol 1986, 13:23–32.
24. Schulman P, McCarroll K, Cooper M, et al.: Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin’s disease: a CALGB study. Med Pediatr Oncol 1990, 18:482–490. DOI: 10.1002/mpo.2950180609
25. Pfreundschuh M, Rueffer U, Lathan B, et al.: Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol 1994, 12:580–592.
26. Hagemeister F, Tannir N, McLaughlin P, et al.: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol 1987, 5:556–563.
27. Rodriguez J, Rodriguez M, Fayad L, et al.: ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood 1999, 93:3632–3641.
28. Pfreundschuh MG, Schoppe WD, Fuchs R: Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin’s disease refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): a multi-center trial of the German Hodgkin’s study group. Cancer Treat Rep 1987, 71:1203–1212.
29. Cowill R, Crump M, Couture F: Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995, 13:396–403.
30. Velasquez WS, Jagannath S, Hagemeister FB: Dexamethasone, high-dose ara-C and cisplatin as salvage treatment for relapsing Hodgkin’s disease. Proc Am Soc Hematol 1986, 68:242–249.
31. Josting A, Reiser M, Rueffer U, et al.: Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol 2000, 18:332–339.
32. Sweetenham J, Taghipour G, Milligan D, et al.: High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997, 20:745–751. DOI: 10.1038/sj.bmt.1700963
33. Bierman P, Bagin R, Jagannath S, et al.: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 1993, 4:767–774.
34. Jones R, Piantadosi S, Mann R, et al.: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 1990, 8:527–534.
35. Josting A, Katay I, Rueffer U, et al.: Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (dexa-BEAM). Ann Oncol 1998, 9:289–295. DOI: 10.1023/A:1008283909959
36. Linch D, Winfield D, Goldstone A, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993, 341:1051–1054. DOI: 10.1016/0140-6736(93)92411-L
37. Schmitz N, Sextro M, Pfistner B, et al.: HDR-1: high-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin’s disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc ASCO 1999:18a.
38. Josting C, Rudolph M, Mapara Y, et al.: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin’s and aggressive non-Hodgkin’s lymphoma: results of a multicenter phase-II study. Blood 2001, 98:2848a.